Search

Competing Interests: Declaration of interests ABe reports a grant through the University of California San Francisco (UCSF) from the US Agency for International Development (USAID) for the SMART4TB Initiative. RC reports a grant from USAID. HC is a member of the Data Safety Monitoring Board for the TRIAD study. CMD reports grants from the US National Institutes of Health (NIH), WHO, German Ministry of Education and Research, German Alliance for Global Health Research, USAID, FIND, German Center for Infection Research, UNAIDS, and Roche Diagnostics; is an academic editor for PLOS Medicine; and is a member of the WHO technical advisory group for tuberculosis diagnostics. EG is a board member for the TB Alliance and reports a grant from USAID for the SMART4TB Initiative. JH reports a grant from the Stop TB Partnership Private Sector Constituency. NH is a member of the British Parliament and co-chair of the Global TB Caucus. PHo reports a grant from USAID for the SMART4TB Initiative. AKi reports personal fees and a contract through UCSF (which also provides travel support) from USAID for the SMART4TB Initiative. IK holds a leadership position at the Save the Children Federation. EL reports personal fees from USAID for the SMART4TB initiative and held a leadership position with Treatment Action Group. PN reports a grant from USAID for the SMART4TB Initiative. MRe reports a grant from USAID for the SMART4TB Initiative. MO reports grants from the Global Fund, Johnson & Johnson, and Cepheid. MP serves as an advisor for the Bill & Melinda Gates Foundation, Foundation for Innovative New Diagnostics, WHO, and Stop TB Partnership. PS reports stock in Hyfe AI. AV reports a grant from Johnson & Johnson. GEV reports grants from the NIH/National Institute of Allergy and Infectious Diseases, Harvard Medical School, Harvard Global Health Institute, Unitaid/Partners in Health, and USAID; and is a protocol co-vice chair for a study with the TB Alliance and for a study with Janssen. GY reports grants from the Gates Foundation and WHO. AZ reports personal fees from Open Consultants. AC reports grants from the US NIH, Global Health Labs, and USAID; and is a member of the Centers for Disease Control and Prevention Advisory Council on Elimination of TB. PHe reports a grant from the Gates Foundation. The remaining authors declare no competing interests.

Objectives: To identify and summarize existing global knowledge gaps on antimicrobial resistance (AMR) in human health, focusing on the World Health Organization (WHO) bacterial priority pathogens, Mycobacterium tuberculosis, and selected fungi., Methods: We conducted a scoping review of gray and peer-reviewed literature, published in English from January 2012 through December 2021, that reported on the prevention, diagnosis, treatment, and care of drug-resistant infections. We extracted relevant knowledge gaps and, through an iterative process, consolidated those into thematic research questions., Results: Of 8409 publications screened, 1156 were included, including 225 (19.5%) from low- and middle-income countries. A total of 2340 knowledge gaps were extracted, in the following areas: antimicrobial research and development, AMR burden and drivers, resistant tuberculosis, antimicrobial stewardship, diagnostics, infection prevention and control, antimicrobial consumption and use data, immunization, sexually transmitted infections, AMR awareness and education, policies and regulations, fungi, water sanitation and hygiene, and foodborne diseases. The knowledge gaps were consolidated into 177 research questions, including 78 (44.1%) specifically relevant to low- and middle-income countries and 65 (36.7%) targeting vulnerable populations., Conclusion: This scoping review presents the most comprehensive compilation of AMR-related knowledge gaps to date, informing a priority-setting exercise to develop the WHO Global AMR Research Agenda for the human health sector., Competing Interests: Declaration of Competing Interest ZD, KvW, and SBe are World Health Organization (WHO) employees. AC was a WHO employee. SBu and DD are consultants to WHO. RLH was a consultant to WHO and is also supported by the Wellcome Trust (106680/Z/14/Z). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of WHO or any of the institutions mentioned., (Copyright © 2023. Published by Elsevier Ltd.)

Competing Interests: We have read the journal’s policy and the authors of this manuscript have the following competing interests: ABS is an Academic Editor on PLOS Medicine’s editorial board.

A report by the Institute of Medicine, Ending Neglect, and sponsored by the US Centers for Disease Control and Prevention, makes recommendations for achieving elimination of tuberculosis in the USA. Among them is the recommendation that a mandatory screening programme be introduced for latent tuberculosis infection in immigrants from high prevalence countries, and that the provision of a permanent residence card (green card) be linked to the completion of an approved course of preventive treatment. We examine the evidence put forward to support this proposal and assess whether such a mandatory programme for preventive treatment of individuals, who do not pose an immediate risk but could pose a risk in the future, meets internationally recognised standards for coercive public-health measures. We conclude from our analysis that there is reason to question (i) the risk analysis, (ii) the estimates of effectiveness of such a policy, (iii) the cost calculations, and (iv) the operational consequences put forward in the report. Moreover, we show that international standards for mandatory screening and treatment are not met.